BrainsWay develops and markets Deep Transcranial Magnetic Stimulation (Deep TMS) systems for treating psychiatric and neurological disorders. Its non-invasive devices use specialized H-coils to stimulate deeper and broader brain regions than conventional TMS, with clearances for major depressive disorder, obsessive-compulsive disorder, and other indications. Customers are primarily hospitals, clinics, and mental health providers adopting neuromodulation therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 11.5 | — | 1.1 | — |
| Q2 2025 | 12.6 | — | 2 | — |
| Q3 2025 | 13.5 | — | 1.6 | — |
| Q4 2025 | 14.5 | — | 2.9 | — |
| Q1 2026 | 15.5 | 34.6% | 2.3 | 106.9% |
| Q2 2026 | 17.1 | 35.4% | 2.7 | 33.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Arko Corp. (ARKO), Solid Power, Inc. (SLDP), Concrete Pumping Holdings, Inc. (BBCP), Citizens & Northern Corporation (CZNC), Bleichroeder Acquisition Corp. III (BCCQ), REGENXBIO Inc. (RGNX)